BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 17683621)

  • 21. Outcome of Idiopathic Membranous Nephropathy: A Retrospective Study.
    Rozenberg I; Kotliroff A; Zahavi T; Benchetrit S
    Isr Med Assoc J; 2018 Mar; 20(3):186-189. PubMed ID: 29527859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
    Karim MY; Pisoni CN; Ferro L; Tungekar MF; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR
    Rheumatology (Oxford); 2005 Oct; 44(10):1317-21. PubMed ID: 16049051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
    du Buf-Vereijken PW; Branten AJ; Wetzels JF;
    Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
    Branten AJ; Wetzels JF
    Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children.
    Lau KK; Jones DP; Hastings MC; Gaber LW; Ault BH
    Pediatr Nephrol; 2006 May; 21(5):655-62. PubMed ID: 16570203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection and clinical significance of glomerular M-type phospholipase A
    Liu H; Luo W; Gong S; Ding X
    Intern Med J; 2016 Nov; 46(11):1318-1322. PubMed ID: 27554390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporin A treatment for idiopathic membranous nephropathy.
    Yao X; Chen H; Wang Q; Tang Z; Hu W; Yin G; Liu Z; Li L
    Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
    Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
    Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.
    Goumenos DS; Kalliakmani P; Tsakas S; Sotsiou F; Vlachojannis JG
    Clin Nephrol; 2004 Jan; 61(1):17-24. PubMed ID: 14964453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
    Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
    Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
    Sahin GM; Sahin S; Kantarci G; Ergin H
    Nephrology (Carlton); 2007 Jun; 12(3):285-8. PubMed ID: 17498124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idiopathic membranous nephropathy: diagnosis and treatment.
    Fervenza FC; Sethi S; Specks U
    Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to immunosuppressive therapy in PLA
    Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
    BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy.
    Cattran DC
    Semin Nephrol; 2003 May; 23(3):272-7. PubMed ID: 12838495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Willems HL; Wetzels JF
    Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
    Dumoulin A; Hill GS; Montseny JJ; Meyrier A
    Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy.
    Heeringa SF; Branten AJ; Deegens JK; Steenbergen E; Wetzels JF
    Nephrol Dial Transplant; 2007 Aug; 22(8):2201-7. PubMed ID: 17442739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy.
    Xie H; Li C; Wen Y; Ye W; Cai J; Li H; Li X; Li X
    Int Urol Nephrol; 2020 Feb; 52(2):337-342. PubMed ID: 31820359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria.
    Matsumoto Y; Shimada Y; Nojima Y; Moriki T
    Ren Fail; 2013 Aug; 35(7):936-41. PubMed ID: 23815417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.
    Kasitanon N; Petri M; Haas M; Magder LS; Fine DM
    Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.